ENTRY       D07086                      Drug
NAME        Rivaroxaban (JAN/USAN/INN);
            Xarelto (TN)
PRODUCT     XARELTO (Aphena Pharma Solutions - Tennessee)
            XARELTO (Cardinal Health 107)
            XARELTO (Janssen Pharmaceuticals)
FORMULA     C19H18ClN3O5S
EXACT_MASS  435.0656
MOL_WEIGHT  435.8813
CLASS       Blood modifier agent
             DG01950  Antithrombotic agent
              DG01662  Factor Xa inhibitor
            Metabolizing enzyme substrate
             DG02954  CYP2J2 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Transporter substrate
             DG01665  ABCB1 substrate
             DG01913  ABCG2 substrate
REMARK      Therapeutic category: 3339
            ATC code: B01AF01
            Product: D07086<JP/US>
EFFICACY    Antithrombotic, Factor Xa inhibitor
COMMENT     Prophylaxis of venous thromboembolism
TARGET      F10 [HSA:2159] [KO:K01314]
  PATHWAY   hsa04610(2159)  Complement and coagulation cascades
METABOLISM  Enzyme: CYP3A4 [HSA:1576], CYP2J2 [HSA:1573]
            Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429]
INTERACTION  
STR_MAP     map07049  Antithrombosis agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             B BLOOD AND BLOOD FORMING ORGANS
              B01 ANTITHROMBOTIC AGENTS
               B01A ANTITHROMBOTIC AGENTS
                B01AF Direct factor Xa inhibitors
                 B01AF01 Rivaroxaban
                  D07086  Rivaroxaban (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Blood Products and Modifiers
              Anticoagulants
               Factor Xa Inhibitors, Direct
                Rivaroxaban
                 D07086  Rivaroxaban (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              33  Blood and body fluid agents
               333  Anticoagulants
                3339  Others
                 D07086  Rivaroxaban (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Blood modifier agent
              DG01950  Antithrombotic agent
               DG01662  Factor Xa inhibitor
                D07086  Rivaroxaban
             Metabolizing enzyme substrate
              DG02954  CYP2J2 substrate
               D07086  Rivaroxaban
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D07086  Rivaroxaban
             Transporter substrate
              DG01665  ABCB1 substrate
               D07086  Rivaroxaban
              DG01913  ABCG2 substrate
               D07086  Rivaroxaban
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Serine peptidases
                F10
                 D07086  Rivaroxaban (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D07086
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D07086
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D07086
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D07086
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D07086
             Drug transporters
              D07086
DBLINKS     CAS: 366789-02-8
            PubChem: 51091428
            ChEBI: 68579
            PDB-CCD: RIV
            LigandBox: D07086
            NIKKAJI: J2.395.184C
ATOM        29
            1   O2x O    18.3529  -15.4520
            2   C1x C    18.3529  -16.8479
            3   C5x C    19.5395  -17.5459
            4   N1y N    20.7958  -16.8479
            5   C1x C    20.7958  -15.4520
            6   C1x C    19.5395  -14.7541
            7   C8y C    21.9824  -17.5459
            8   C8x C    21.9824  -18.9418
            9   C8x C    23.2387  -19.6397
            10  C8y C    24.4253  -18.9418
            11  C8x C    24.4253  -17.5459
            12  C8x C    23.2387  -16.8479
            13  N1y N    25.6118  -19.6397
            14  O5x O    19.5395  -18.9418
            15  C1x C    26.0493  -20.9654
            16  C1y C    27.4451  -21.0290
            17  O7x O    27.8704  -19.6295
            18  C7x C    26.7374  -18.8141
            19  O6a O    26.7311  -17.4063
            20  C1b C    28.2675  -22.0802
            21  N1b N    29.6596  -22.1153
            22  C5a C    30.4027  -20.9007
            23  C8y C    31.8236  -20.9466
            24  O5a O    29.7142  -19.6963
            25  S2x S    32.9956  -21.6562
            26  C8y C    34.1000  -20.7785
            27  C8x C    33.6066  -19.4570
            28  C8x C    32.1973  -19.4479
            29  X   Cl   35.4112  -21.1422
BOND        32
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     5   6 1
            6     1   6 1
            7     4   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11   10  11 1
            12   11  12 2
            13    7  12 1
            14   10  13 1
            15    3  14 2
            16   13  15 1
            17   15  16 1
            18   16  17 1
            19   17  18 1
            20   13  18 1
            21   18  19 2
            22   16  20 1 #Up
            23   20  21 1
            24   21  22 1
            25   22  23 1
            26   22  24 2
            27   23  25 1
            28   25  26 1
            29   26  27 2
            30   27  28 1
            31   23  28 2
            32   26  29 1
///
